Brief: Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia
14/01/2025 13:32
Jan 14 (Reuters) - VistaGen Therapeutics Inc VTGN.O :
* VISTAGEN ANNOUNCES POSITIVE RESULTS FROM EXPLORATORY PHASE
2A
STUDY OF PH284 IN CANCER CACHEXIA
* VISTAGEN ANNOUNCES POSITIVE RESULTS FROM EXPLORATORY PHASE
2A
STUDY OF PH284 IN CANCER CACHEXIA
* VISTAGEN THERAPEUTICS INC - PH284 DEMONSTRATES NO SERIOUS
ADVERSE EVENTS
* VISTAGEN THERAPEUTICS INC - PHASE 2A STUDY EVALUATES
EFFICACY,
SAFETY, AND TOLERABILITY OF PH284
Source text: ID:nBw9K3WzGa
Further company coverage: VTGN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vistagen Therapeutics
See all newsBrief: Vistagen TherapeuticsSays Fasedienol Nasal Spray Well-Tolerated With No New Drug-Related Safety Findings After 12 Months
VistaGen Q1 revenue rises on licensing agreement expiration
Brief: VistaGen Q1 EPS USD -0.3
Vistagen Therapeutics Inc expected to post a loss of 36 cents a share - Earnings Preview
Brief: Vistagen Appoints Douglas J. Williamson To Its Board Of Directors